Patents by Inventor Ryan Hudson

Ryan Hudson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12371414
    Abstract: The present disclosure relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein the variable are as described herein, and compositions and uses of same for treating neurological disorders.
    Type: Grant
    Filed: April 5, 2024
    Date of Patent: July 29, 2025
    Assignee: Neumora Therapeutics, Inc.
    Inventors: Paul Dransfield, Dilinie Fernando, James Harvey, Brian Sparling, John Stellwagen, Zhihua Ma, Anne-Marie Beausoleil, Ryan Hudson
  • Patent number: 12358931
    Abstract: Disclosed is a compound of the formula: or a pharmaceutically-acceptable salt thereof. Also disclosed is a method of inhibiting a Janus kinase enzyme in a mammal using the compound.
    Type: Grant
    Filed: September 5, 2023
    Date of Patent: July 15, 2025
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Ryan Hudson, Jennifer Kozak, Paul R. Fatheree, Dante D. Podesto, Gary E. L. Brandt, Melissa Fleury, Anne-Marie Beausoleil
  • Publication number: 20250188055
    Abstract: The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity. Selected compounds in this class promote apoptosis in senescent cells, and are being developed for treating senescent-related conditions. Selected compounds in this class promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.
    Type: Application
    Filed: December 23, 2024
    Publication date: June 12, 2025
    Inventors: Anne-Marie Beausoleil, Ryan Hudson
  • Publication number: 20250074888
    Abstract: Compounds are provided for modulating NLRP3 inflammasome generally, or for treating a NLRP3 inflammasome dependent condition more specifically, by contacting the NLRP3 inflammasome or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, R11, R12, and R13 are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.
    Type: Application
    Filed: December 28, 2022
    Publication date: March 6, 2025
    Inventors: Anne-Marie BEAUSOLEIL, Ryan HUDSON
  • Patent number: 12221433
    Abstract: The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity. Selected compounds in this class promote apoptosis in senescent cells, and are being developed for treating senescent-related conditions. Selected compounds in this class promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: February 11, 2025
    Assignee: Unity Biotechnology, Inc.
    Inventors: Anne-Marie Beausoleil, Ryan Hudson
  • Patent number: 12172994
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Grant
    Filed: October 3, 2023
    Date of Patent: December 24, 2024
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Jennifer Kozak, Ryan Hudson, Gary E. L. Brandt, Robert Murray McKinnell, Marta Dabros, Jerry Nzerem
  • Publication number: 20240383884
    Abstract: Provided herein, inter alia, are methods and compounds for modulating Interleukin-2-inducible T-cell kinase.
    Type: Application
    Filed: February 12, 2024
    Publication date: November 21, 2024
    Inventors: Ryan Hudson, Anne- Marie Beausoleil
  • Publication number: 20240294492
    Abstract: The present disclosure relates to compounds of Formula (I). and pharmaceutically acceptable salts thereof, wherein the variable are as described herein, and compositions and uses of same for treating neurological disorders.
    Type: Application
    Filed: April 5, 2024
    Publication date: September 5, 2024
    Inventors: Paul Dransfield, Dilinie Fernando, James Harvey, Brian Sparling, John Stellwagen, Zhihua Ma, Anne-Marie Beausoleil, Ryan Hudson
  • Publication number: 20240246928
    Abstract: The present disclosure relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein the variable are as described herein, and compositions and uses of same for treating neurological disorders.
    Type: Application
    Filed: December 1, 2023
    Publication date: July 25, 2024
    Inventors: Paul Dransfield, Dilinie Fernando, James Harvey, Brian Sparling, John Stellwagen, Zhihua Ma, Anne-Marie Beausoleil, Ryan Hudson
  • Patent number: 11993580
    Abstract: The present disclosure relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein the variable are as described herein, and compositions and uses of same for treating neurological disorders.
    Type: Grant
    Filed: December 1, 2023
    Date of Patent: May 28, 2024
    Assignee: Neumora Therapeutics, Inc.
    Inventors: Paul Dransfield, Dilinie Fernando, James Harvey, Brian Sparling, John Stellwagen, Zhihua Ma, Anne-Marie Beausoleil, Ryan Hudson
  • Publication number: 20240158389
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Application
    Filed: October 3, 2023
    Publication date: May 16, 2024
    Inventors: Jennifer Kozak, Ryan Hudson, Gary E.L. Brandt, Robert Murray McKinnell
  • Patent number: 11982100
    Abstract: According to an aspect of the present invention, there is provided a device for attaching to a door or window, comprising: a flat surface configured to attach to a door or window; an adhesive applied to the flat surface; a diagonal surface; a concave surface connecting the diagonal surface and the flat surface; and a solid body positioned between the flat surface, the diagonal surface, and the concave surface. The device may alternatively have one or more screw holes spanning the thickness of the device.
    Type: Grant
    Filed: October 4, 2023
    Date of Patent: May 14, 2024
    Inventor: Ryan Hudson-Peralta
  • Publication number: 20240132520
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat inflammatory bowel diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: September 5, 2023
    Publication date: April 25, 2024
    Inventors: Ryan Hudson, Jennifer Kozak, Paul R. Fatheree, Dante D. Podesto, Gary E.L. Brandt, Melissa Fleury, Anne-Marie Beausoleil, Xiaojun Huang, Venkat R. Thalladi
  • Patent number: 11897874
    Abstract: Provided herein, inter alia, are methods and compounds for modulating Interleukin-2-inducible T-cell kinase.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: February 13, 2024
    Assignee: Corvus Pharmaceuticals, Inc.
    Inventors: Ryan Hudson, Anne-Marie Beausoleil
  • Publication number: 20230365534
    Abstract: Compounds are provided for modulating NLRP3 inflammasome generally, or for treating a NLRP3 inflammasome dependent condition more specifically, by contacting the NLRP3 inflammasome or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein X, R1, R2, R3, R4, R5, R8, R9, R10, R1, R12, R13, and n are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.
    Type: Application
    Filed: May 12, 2023
    Publication date: November 16, 2023
    Inventors: Anne-Marie Beausoleil, Ryan Hudson
  • Patent number: 11814377
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: November 14, 2023
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Jennifer Kozak, Ryan Hudson, Marta Dabros, Jerry Nzerem
  • Patent number: 11780852
    Abstract: Disclosed are methods for treating Crohn's disease using a compound of the formula: or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: October 10, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Ryan Hudson, Jennifer Kozak, Dante D. Podesto, Xiaojun Huang, Venkat R. Thalladi
  • Publication number: 20230298739
    Abstract: A system comprises a plurality of first computing devices, wherein each first computing device is wearable by a user or is affixed to an asset within an environment and configured to generate and transmit a message; and a plurality of second computing devices installed within the environment, wherein a portion of the plurality of second computing devices are configured to detect at least one of the plurality of first computing devices, receive messages transmitted by a detected first computing device, and timestamp the messages before transmitting the messages to a computing server system. The computing server system is configured to determine at least a location of the detected first computing device based at least upon the messages received from the portion of the plurality of second computing devices.
    Type: Application
    Filed: August 5, 2021
    Publication date: September 21, 2023
    Applicant: Geonavo Positioning Systems, Inc.
    Inventors: Malcolm Williams, Stewart Ian Hardie, Ioan Romulus Curticapean, Benjamin Griffen Ryan Hudson
  • Patent number: 11608354
    Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: March 21, 2023
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Ryan Hudson, Daniel D. Long, Donna A. A. Wilton, Mandy Loo, Patrick J. Brassil
  • Publication number: 20220396573
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Application
    Filed: June 30, 2022
    Publication date: December 15, 2022
    Inventors: Jennifer Kozak, Ryan Hudson, Gary E.L. Brandt, Robert Murray McKinnell